U.S. markets closed

Alzamend Neuro, Inc. (ALZN)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.8500-0.0458 (-5.11%)
At close: 04:00PM EDT
0.8510 +0.00 (+0.12%)
After hours: 05:31PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Continuation Wedge (Bullish)

Continuation Wedge (Bullish)

Previous Close0.8958
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.8485 - 0.9000
52 Week Range0.7400 - 11.9100
Avg. Volume53,583
Market Cap5.837M
Beta (5Y Monthly)0.02
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ALZN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Alzamend Neuro, Inc.
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverIn this edition, European interest-rate cuts on the horizon; firm opportunities among drug and biopharma firms; and reports Tesla's affordable vehicle will be canceled; and Lazard, PVH, and Genmab.
    Fair Value
    Economic Moat
    7 days agoMorningstar
View more
  • Insider Monkey

    Insiders Are Buying These 11 Penny Stocks

    In this article, we will take a detailed look at Insiders Are Buying These 11 Penny Stocks. For a quick overview of such stocks, read our article Insiders Are Buying These 5 Penny Stocks. US stock market started the second quarter of 2024 in the red, driven by rising treasury yields, broader volatility and uncertainty around rate cuts […]

  • Benzinga

    EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year

    Alzamend Neuro Inc (NASDAQ: ALZN) received a "Study May Proceed" letter from the FDA for the initiation of study AL001-PTSD01, a Phase 2A study of AL001 for post-traumatic stress disorder (PTSD). "Although lithium does not have an FDA-approved indication for PTSD, it has been prescribed off-label for this purpose for decades," said Stephan Jackman, Chief Executive Officer of Alzamend. "If we can develop a next-generation lithium product (AL001) that would not routinely require therapeutic drug m

  • Benzinga

    EXCLUSIVE: Alzamend Neuro Submits IND For Phase IIA Trial Of Next-Gen Lithium Candidate In Major Depressive Disorder

    Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA to initiate AL001-MDD01, a Phase IIA plasma/brain pharmacokinetics clinical study of AL001 for adjunctive treatment of patients with major depressive disorder (MDD). Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for treating Alzheimer’s, BD, MDD, and PTSD. Lithium, although not FDA-approved for MDD augmentation, has been used off-label for y